Patents by Inventor Motowo Nakajima
Motowo Nakajima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220370395Abstract: The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.Type: ApplicationFiled: July 1, 2022Publication date: November 24, 2022Inventors: Masahiro Ishizuka, Takuya ISHII, Motowo NAKAJIMA, Yuya KITAJIMA
-
Publication number: 20200030275Abstract: The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.Type: ApplicationFiled: April 12, 2018Publication date: January 30, 2020Inventors: Masahiro ISHIZUKA, Takuya ISHII, Motowo NAKAJIMA, Yuya KITAJIMA
-
Patent number: 10022345Abstract: The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs.Type: GrantFiled: November 30, 2015Date of Patent: July 17, 2018Assignee: SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata
-
Publication number: 20180125805Abstract: The present invention addresses the problem of providing a prophylactic/therapeutic agent which is inexpensive, has little adverse side effects and is effective against persistent virus infections. A 5-aminolevulinic acid compound represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group or an aralkyl group) or a salt thereof can be used as a prophylactic and/or therapeutic agent for virus infections to prevent proliferation of viruses.Type: ApplicationFiled: March 18, 2016Publication date: May 10, 2018Applicant: SBI Pharmaceuticals Co., Ltd.Inventors: Tohru TANAKA, Motowo NAKAJIMA, Takeshi HARA
-
Patent number: 9962350Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.Type: GrantFiled: July 10, 2015Date of Patent: May 8, 2018Assignees: SBI Pharmaceuticals Co., Ltd., Yamagata UniversityInventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
-
Patent number: 9937138Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: April 10, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9901558Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: February 27, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9895331Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).Type: GrantFiled: July 11, 2013Date of Patent: February 20, 2018Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
-
Publication number: 20170202210Abstract: Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.Type: ApplicationFiled: February 24, 2015Publication date: July 20, 2017Inventors: Tohru TANAKA, Motowo NAKAJIMA, Urara OTA, Hidenori ITO, Ko RII
-
Patent number: 9707196Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.Type: GrantFiled: October 5, 2012Date of Patent: July 18, 2017Assignees: SBI Pharmaceuticals Co., Ltd., National University Corporation Kochi UniversityInventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata
-
Publication number: 20170157074Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.Type: ApplicationFiled: July 10, 2015Publication date: June 8, 2017Inventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
-
Patent number: 9539225Abstract: A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.Type: GrantFiled: October 5, 2012Date of Patent: January 10, 2017Assignee: SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Kiwamu Takahashi
-
Patent number: 9488664Abstract: It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.Type: GrantFiled: January 15, 2013Date of Patent: November 8, 2016Assignee: SBI Pharmaceuticals Co., Ltd.Inventors: Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota
-
Patent number: 9475755Abstract: A method for ameliorating and/or preventing chronic kidney disease includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof as an active ingredient. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters, such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.Type: GrantFiled: October 5, 2012Date of Patent: October 25, 2016Assignee: SBI Pharmaceuticals Co., LtdInventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Satofumi Kawata, Takeo Kohda
-
Patent number: 9474770Abstract: The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.Type: GrantFiled: August 10, 2012Date of Patent: October 25, 2016Assignees: SBI Pharmaceuticals Co., Ltd., Nihon UniversityInventors: Kosaku Kinoshita, Katsuhisa Tanjoh, Akihiro Noda, Atsushi Sakurai, Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe
-
Patent number: 9469598Abstract: A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.Type: GrantFiled: October 5, 2012Date of Patent: October 18, 2016Assignees: SBI Pharmaceuticals Co., Ltd., Tohoku UniversityInventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Takaaki Abe
-
Patent number: 9463175Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.Type: GrantFiled: June 22, 2015Date of Patent: October 11, 2016Assignees: SBI Pharmaceuticals Co., Ltd., The University of TokyoInventors: Tohru Tanaka, Satofumi Kawata, Takeo Kohda, Motowo Nakajima, Kiyoshi Kita
-
Publication number: 20160271090Abstract: The object of the present invention to provide an agent effective for treating and preventing e.g. a disease caused by reduction in frataxin production. The present invention provides a frataxin enhancer comprising 5-aminolevulinic acid (ALA) or a derivative thereof or salts thereof, as well as a therapeutic and/or prophylactic agent for a disease caused by reduction in frataxin production.Type: ApplicationFiled: October 22, 2014Publication date: September 22, 2016Inventors: Taku CHIBAZAKURA, Tohru TANAKA, Fuminori ABE, Motowo NAKAJIMA, Atsuko KAMIYA, Naomi HAGA, Kiwamu TAKAHASHI
-
Patent number: 9399029Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: July 3, 2013Date of Patent: July 26, 2016Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Naomi Haga, Kiwamu Takahashi, Hidenori Ito, Ko Rii
-
Publication number: 20160206582Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: March 9, 2016Publication date: July 21, 2016Applicants: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Ko RII, Kiwamu TAKAHASHI, Naomi HAGA, Fuminori ABE, Tohru TANAKA, Motowo NAKAJIMA, Hidenori ITO